Concurrent Chemoradiation With Concomitant Boost In Locally Advanced Rectal Cancer
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
Neoadjuvant chemoradiation (CRT), is considered the standard treatment of locally advanced
rectal cancer with a positive impact on locoregional control and survival.However, patients
with T4 rectal cancer show high risk of local recurrence after conventional treatment.
Therefore investigators designed a prospective Phase II study on patients with locally
advanced rectal cancer or locally recurrences, to evaluate the efficacy in terms of
pathological response and resectability of concomitant boost RT (55 Gy/5 weeks) with
concurrent Raltitrexed and Oxaliplatin (Tom-Ox) chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi IRCCS Azienda Ospedaliero-Universitaria di Bologna